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Abstract:
Introduction: Concentrations of the total pool of fibronectin in plasma (TFN), and the subset of this pool that contains the alterna-
tively spliced EDA segment (A+FN), are both affected by disease processes, and the latter pool has gained a reputation as a biomarker 
for vascular injury. We therefore wished to determine if changes in either FN pool correlate with clinical outcomes in critically ill 
individuals.
Methods: We analyzed a database for 57 patients with major trauma (n = 33) or sepsis syndrome (n = 24) in which plasma levels of TFN 
and A+FN had been measured at intervals, along with clinical parameters. Logistic regression analysis was performed to detect associa-
tions between predictive variables and three clinical outcomes: 1) the acute respiratory distress syndrome (ARDS), 2) milder acute lung 
injury designated acute hypoxemic respiratory failure (AHRF), and 3) survival to hospital discharge.
Results: An increase in plasma TFN during the first 24 hours of intensive care unit (ICU) observation was negatively associated 
with progression to ARDS (odds ratio 0.98 per 1 microgram (µg)/ml increase, 95% CI (0.97, 1.00)) and AHRF (OR 0.97 per 1 µg/ml 
increase, (0.95, 0.99)), whereas an increase in A+FN over the first 24 hours was positively associated with progression to AHRF (OR 
1.65 per 1 µg/ml increase, (1.04, 2.62)). Additionally, the ratio of the partial pressure of oxygen in arterial blood (PaO2) to the percent-
age of oxygen in inspired air (FIO2) after 24 hours was positively associated with survival (OR 1.01 per 1 unit increase in ratio, (1.00, 
1.03)), along with change in A+FN (OR 1.30 per 1 µg/ml increase, (0.90, 1.88)).
Conclusions: Different FN isoforms may constitute predictive covariate markers for distinct clinical outcomes in critically ill patients. 
The data also suggest that early TFN accumulation in the circulation may confer a clinical benefit to patients at risk for acute lung 
injury.
Keywords: fibronectin, extracellular matrix, alternative splicing, acute lung injury, clinical outcomes
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Introduction
Fibronectins (FNs) are a family of large multifunc-
tional adhesion glycoproteins that exist both in sol-
uble and insoluble forms. Plasma FN (pFN) is the 
designation for the pool of soluble circulating FNs, 
which collectively constitute a major component of 
blood (∼0.6 micromolar in plasma), whereas insolu-
ble extracellular matrix (ECM) FNs are concentrated 
in dense tissue structures, including basement mem-
branes and blood vessel walls.1 FNs are involved 
in the regulation of a wide variety of cellular func-
tions, including adhesion, migration, proliferation, 
and apoptosis.1 Much of this regulation is mediated 
through interactions between FNs and cell surface 
integrin receptors.2,3 The capacity of FNs to regulate 
apoptosis is probably clinically relevant, based upon 
the observation that pFN restricts infarction size in a 
mouse model of cerebral ischemia by penetrating the 
zone of tissue injury and triggering α5β1 integrin-
mediated neuronal upregulation of the anti-apoptosis 
gene Bcl-2.4
Although derived from a single gene, FN isoforms 
differ as a consequence of alternative splicing at three 
major sites. Two of these are ∼90 amino acid type III 
repeating modules that may be completely included or 
excluded from the FN molecule.  Accordingly, they are 
designated “extra type III repeats” A (called “EDA”, 
for “extra domain A”, or EIIIA) and B (called EDB or 
EIIIB). Although no function has yet been assigned 
to EDB, a recognition site for α4β1 and α9β1 integ-
rins is present in the EDA segment.5,6 Since the vast 
bulk of pFN is produced by hepatocytes, which do 
not normally express EDA or EDB,1 pFN in healthy 
subjects is nearly devoid of these  segments.7 In con-
trast, endothelial cells synthesize and secrete a mix-
ture of FN isoforms in which EDA and EDB segments 
are included in ∼15%–40% of total synthesized FN 
monomers.8,9 Such production may contribute to the 
low concentrations of EDA+ FN (A+FN) and EDB+ 
FN (B+FN) that have been detected in the plasma of 
healthy individuals (accounting ,∼1% of the total 
circulating pool of FN).10,11
Total levels of pFN (TFN) fall rapidly after sur-
gery, trauma, burns, and sepsis.12–17 Patients who 
recover from such insults demonstrate a rebound in 
TFN, whereas those who die have been observed to 
exhibit persistently low TFN.1,13,17 These findings, in 
addition to observations that circulating dimeric pFN 
(440–500 kDa) is in an equilibrium with the  insoluble 
multimeric FN in capillary walls, and stimulates 
opsonization of particles within the bloodstream, 
have long suggested that pFN could exert an adaptive 
role in acute vascular injury.1,18–20
In contrast to TFN, levels of A+FN increase after 
major trauma or the onset of sepsis.10 In an earlier 
descriptive analysis of the same patient database 
that we examined for clinical outcomes in this study, 
we found that, compared to levels in healthy sub-
jects, average TFN concentrations were significantly 
reduced for sepsis or trauma patients at the time of 
ICU admission and for at least 24 hours thereafter.10 
In contrast, in comparison to levels in healthy sub-
jects, A+FN levels were significantly increased for 
sepsis or trauma patients upon ICU admission and 
for the subsequent 72 hours, exhibiting a peak mean 
value at 48 hours for the sepsis group and 72 hours 
for the trauma group.10 Plasma levels of B+FN were 
also observed to increase significantly above normal 
levels at 24, 48, and 72 hours following ICU admis-
sion in patients with major trauma.11
Several potential predictors of survival in critically-
ill patients, including severity-of-illness measures,21,22 
levels of intestinal platelet trapping,23 as well as blood 
concentrations of cytokines,24 cytokine receptors,25 
hormones,26 and coagulation-modulating proteins27 
have been studied. Sets of variables have also been 
considered in the prediction of clinical outcome in crit-
ically ill patients, eg, an association has been detected 
between APACHE III score, gas exchange measured 
by the ratio of PaO2 to FIO2 on the third ICU day, and 
mortality in trauma patients with ARDS.28
To determine if particular species among the FN 
family of alternatively spliced adhesion proteins con-
stitute biomarkers for clinical outcomes in patients 
with acute systemic illness—possibly in combination 
with other putative markers of microvascular dys-
function such as the PaO2/FIO2 ratio
28—and to look 
for clues to the physiologic significance of changes in 
plasma levels of TFN and A+FN, we performed logis-
tic regression analysis to seek associations between 
the changes in such levels and three outcomes: 1) 
severe acute lung injury, fulfilling criteria for ARDS,29 
2) a milder form of acute lung injury, designated 
“acute hypoxemic respiratory failure” (AHRF), which 
is clinically similar to the currently widely accepted 
acute lung injury (ALI) designation,30 and 3) survival. 
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We have found that the change in plasma TFN levels 
between 0 and 24 hours of ICU observation (∆TFN) 
constitutes a predictive covariate for progression to 
acute lung injury. Specifically, increases in TFN dur-
ing this period were associated with reduced odds of 
progression to ARDS. Among six candidate covari-
ates, ∆TFN alone was the best predictor of ARDS, 
using a model selection criterion. For prediction of 
AHRF, three variables in combination were selected: 
∆TFN, ∆A+FN (the change in A+FN levels between 0 
and 24 hours of ICU observation) and an indicator for 
risk-group.
Materials and Methods
Study design
We retrospectively analyzed a clinical database 
that had originally been collected for a cohort of 59 
patients (34 with acute major trauma and 25 with 
sepsis syndrome) who were admitted to the ICUs 
of Harborview Medical Center in Seattle, WA in 
1985–1986. The research was approved by the institu-
tional review board at the University of Washington, 
conducted according to the principles of the Declara-
tion of Helsinki, and informed consent was obtained 
in all instances. During the current study, two of the 
59 original patients were eliminated from analysis: 
1) a patient originally included in the trauma group10 
was retrospectively determined to also have suf-
fered Pneumocystis carinii pneumonia in association 
with the acquired immune deficiency syndrome, and 
2) a patient in the sepsis group was determined to have 
developed ARDS before admission to the ICU. We 
have therefore retrospectively analyzed data from the 
remaining 57 patients (33 with trauma, and 24 with 
sepsis) (Fig. 1, panel A, “total patient population”), 
none of whom exhibited either AHRF or ARDS upon 
induction into the study.
Two or more of the following criteria were required 
for inclusion in the major trauma group: 1) pelvic or 
long bone fracture (n = 26), 2)  intra-abdominal injury 
requiring laparotomy (n = 21), 3) pulmonary contu-
sion, flail chest, or intrathoracic injury requiring tho-
racotomy (n = 20), or 4) transfusion of .8 units of 
whole blood and/or packed red cells in a 12 hour period 
(n = 20); whereas sepsis syndrome was defined as sys-
temic infection with a deleterious systemic response.31 
The data set includes serial plasma levels of TFN and 
A+FN, which we measured in samples collected via 
indwelling arterial catheters at 24 hour intervals, up 
to a maximum of 72 hours, as reported previously.10 
Methods used in the preparation and storage of plasma 
samples, the quantitative immunoassays for measure-
ment of TFN and A+FN, and descriptive statistics 
regarding levels of the two categories of FN in the two 
groups of patients have been published.10
The following demographic variables had been 
recorded for each patient at the time of the original 
study: age in years, sex, and risk group (trauma or sep-
sis, as defined above) (Fig. 1, panel A, “predictors”). 
In addition, the following physiologic parameters 
were measured and recorded at 0, 24, 48 and 72 hours 
following ICU admission: total static thoracic com-
pliance (mls/cm H2O), PaO2, FIO2, and a compos-
ite chest x-ray score. The latter was derived from a 
4-quadrant analysis of each chest radiograph in which 
right and left lungs were each divided into upper and 
lower quadrants by a horizontal line 2 centimeters 
below the carina. Each quadrant was then scored on 
a 0–4 point scale, and the composite score was cal-
culated by adding the individual quadrant scores and 
dividing by 4 (Fig. 1, panel B). For example, a score 
of 0 indicated an absolutely clear chest x-ray, while 
a score of 4 indicated total opacification of all lung 
fields. Chest x-ray scoring was performed at the time 
of initial patient accrual by a chest radiologist and a 
pulmonary physician. The ratio of PaO2 to FIO2 (PaO2/
FIO2 ratio) was calculated as an indicator of sever-
ity of hypoxemia for each patient at each time point. 
Finally, an APACHE II score32 was calculated and 
recorded for each patient, based on the worst  values 
over the course of the first 24 hours (“APACHE II 
0–24” in Fig. 1, panel A).
Although ARDS29 was the sole accepted  clinical 
designation for acute hypoxemic lung injury at the 
time of the original study, we recognized at that time 
that acute lung injury represents a continuum of abnor-
malities, as reflected by our incremental radiographic 
scoring system (Fig. 1, panel B),  Nevertheless, the 
American European Consensus Conference (AECC) 
definition of acute lung injury (ALI)30 had not yet 
been developed, and our original composite CXR 
scores do not permit retrospective application of the 
ALI definition. However, the scoring system allows 
us to identify a group of patients with a milder degree 
of hypoxemic respiratory failure approximating 
what many would consider to be ALI. We define this 
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 condition, designated “acute hypoxemic respiratory 
failure” (AHRF), as both a PaO2/FIO2 ratio ,300 and 
a composite CXR score .1.5. Survival is defined as 
discharge from the hospital, regardless of the total 
duration of hospitalization.
Statistical analysis
Several patients died or were transferred out of the 
ICU before 72 hours, leading to progressive attrition 
in the subject population at successive time points. 
For example, FN levels were measured for 57 (33 
trauma and 24 sepsis), 45 (26 trauma and 19 sepsis), 
42 (24 trauma and 18 sepsis), and 37 (22 trauma and 
15 sepsis) patients at 0, 24, 48, and 72 hours. We there-
fore limited our analysis to the 0 and 24 hour time 
points (for which data are available for 45 patients) 
in order to focus on the time period containing the 
maximum density of data, while permitting study of 
clinical time courses.
Our goal was to determine a reduced set of covari-
ates which have high utility in predicting clinical out-
come. For each of the binary outcomes (ARDS, AHRF, 
and survival), model selection was performed by suc-
cessively eliminating predictors from a full model, 
using the Akaike Information Criterion (AIC).33,34 
We used the “step AIC” function, available in the 
MASS library of the statistical software  package R,35 
to carry out the elimination steps. Goodness of fit was 
assessed using measures of deviance, 2-by-2 cross-
 classifications of predicted versus observed outcomes, 
and (on a patient-by-patient basis) residuals and influ-
ence values. We used Agresti36 as a general reference 
on logistic regression.
Prediction of ArDS and AhrF
Among the total population of 57 patients, logistic 
regression models for ARDS or AHRF status were 
estimated using the subsample of 45 patients who had 
complete data at admission for age, sex, risk group 
(trauma or sepsis), APACHE, and plasma concen-
trations of TFN and A+FN at the 0 and 24 hour time 
points (Fig. 1, panel A). Static thoracic compliance, 
chest x-ray score, and PaO2/FIO2 ratios were excluded 
from this analysis, as these are primary variables used 
in the diagnosis of acute lung injury,37 and their inclu-
sion as predictors of ARDS or AHRF would lead to 
logical circularities.
∆TFN and ∆A+FN, calculated by subtracting the 
levels of TFN and A+FN at 0 hours from their respec-
tive levels at 24 hours, are entered as predictors in a 
n = 57
n = 45 n = 34
Total patient population:
Model for: Acute lung injury
(ARDS or AHRF)
Survival status
Predictors
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
NA
NA
NA
NA
Age
Sex
Risk
Apache II 0–24
Compliance, 0 hr
CXR, 0 hr
PaO2/FIO2, 0 hr
PaO2/FIO2, 24 hr
∆TFN, 0 to 24 hr
∆A+FN, 0 to 24 hr
A B
Chest X-ray severity scoring system
Score Description
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0 Complete white-out of quadrant
Some fluffy patches
Fluffy patchy densities involving ≥1/2 the
quadrant
Non-confluent alveolar filling involving ≥1/2 the
quadrant
Loss of vascular definition involving ≥1/2 the
quadrant
Anything less than 1.0, but not normal
Normal
Non-confluent alveolar filling involving <1/2 the
quadrant or anything less than a 2.0
Partial white-out of quadrant
Figure 1. experimental schema. A) patient groups. A total population of 57 patients (33 with trauma and 24 with sepsis) was studied via logistic regres-
sion analysis of data collected shortly after admission to the IcU. no patient within this group, designated by the intact “pie” at the top of the panel, had 
ArDS or AhrF upon IcU admission. For the purpose of determining logistic regression models for progression to acute lung injury (ArDS or AhrF), a 
subsample of 45 patients was studied (pie remnant to the lower left). For analysis of survival, a group of 34 patients, each of whom was also included in the 
45 patient subsample cited above, was analyzed (pie remnant to the lower right) (inclusion criteria for each patient subsample are described in Methods). 
Demographic and physiologic parameters, as well as changes in concentrations of TFn and A+Fn are included in the list of potential predictors available 
for inclusion in logistic regression models for the prediction of acute lung injury or survival. B) chest x-ray scoring system. each chest x-ray was divided 
into quadrants, each of which was scored according to criteria described in the right panels. The resulting quadrant scores were summed and divided by 
4 to yield a composite chest x-ray severity score.
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model for acute lung injury, along with age, sex, risk 
group, APACHE II 0–24 and an intercept. We call this 
the “full” model for acute lung injury (Fig. 1, panel A).
Prediction of survival
A logistic regression model for survival status was esti-
mated using the subsample of n = 34 patients who had 
complete data for age in years, sex, risk-group (trauma 
or sepsis), APACHE II 0–24, thoracic compliance at 
0 hours, chest x-ray score at 0 hours, and complete data 
for PaO2 and FIO2, as well as concentrations of TFN and 
A+FN, at the 0 and 24 hour time points (Fig. 1, panel A). 
The PaO2/FIO2 ratios after 0 and 24 hours of ICU obser-
vation are entered as predictors into a model for survival 
status, along with an intercept, ∆TFN, ∆A+FN and the 
other variables listed immediately above. We call this 
the “full” model for survival status.
Results
Subject characteristics
Sepsis patients were older (average age 49 versus 38), 
and had a higher rate of acute lung injury (ARDS or 
AHRF), and a lower rate of survival, than the trauma 
group (Table 1). Nevertheless, the time interval ana-
lyzed in this study—the first 24 hours following ICU 
admission (time = 0 to 24 hours)—was similar, rela-
tive to clinical course, for the two groups. For exam-
ple, the “risk-to-draw time” (time of diagnosis of 
sepsis syndrome or major trauma to the time = 0 hour 
blood draw), which was available for 50 patients, 
did not differ significantly for 19 sepsis patients 
(16.8 ± 12.1 hours) versus 31 trauma patients (mean 
17.6 ± 7.0 hours; two-tailed t-test, P = n.s.). Within 
the subsample of 45 patients analyzed for progression 
to ARDS or AHRF (Fig. 1, panel A), the risk-to-draw 
time also did not differ significantly for the 19 with 
sepsis (16.8 ± 12.1 hours) versus the 26 with trauma 
(17.2 ± 6.9 hours). Similarly, among the subsample 
of 34 patients analyzed for survival (Fig. 1, panel A), 
this value also did not differ significantly for the 13 
with sepsis (17.8 ± 12.7 hours) versus the 21 with 
trauma (18.3 ± 6.3 hours) (Table 1). Of note, how-
ever, is that the time from hospital admission to the 
first blood draw (“admit-to-draw time”, available 
for 50 patients) was significantly greater for the 
sepsis group (97.6 ± 135 hours) than for the trauma 
group (15.0 ± 8.1 hours; two-tailed t-test, P = 0.003) 
(Table 1).
Logistic regression for ArDS
Of the predictors in the full model, only ∆TFN, along 
with an intercept, remains in the best sub-model chosen 
by backwards elimination with the AIC (Table 2, top). 
The odds ratio for a unit (1 µg/ml) increase in TFN at 
24 hours, as compared to 0 hours, is 0.98, with 95% 
confidence interval (0.97, 1.00). The odds ratio for a 
20-unit (20 µg/ml) increase in TFN is 0.73, with 95% 
CI (0.55, 0.96), suggesting an average 27% reduction 
in the odds of an ARDS diagnosis for a change in TFN 
typical of the trauma sample (see Table 1). Table 3 
(top) gives a cross-classification of observed versus 
predicted ARDS status using the logistic regression 
model of Table 2. As shown, of the 19 patients pre-
dicted by the model to develop ARDS, 12 did.
Logistic regression for AhrF
Of the predictors in the “full” model: age, sex, risk-
group, APACHE II 0–24, ∆TFN, and ∆A+FN, four 
variables (∆TFN, ∆A+FN, risk group, and an inter-
cept) remain in the best sub-model (Table 2, middle). 
The odds ratio for a unit (1 µg/ml) increase in TFN at 
24 hours, as compared to 0 hours, is 0.97, with 95% 
confidence interval (0.95, 0.99). Contrary to TFN, an 
increase in A+FN between 0 and 24 hours is associ-
ated with an increase in the odds of an AHRF diag-
nosis (OR 1.65 per1 µg/ml, 95% CI (1.04, 2.62)). 
Finally, risk-group remains in the predictive set of 
variables. Table 3 (middle) gives a cross-classifica-
tion of observed versus predicted AHRF status using 
the logistic regression model of Table 2. As can be 
seen, of the 33 patients predicted by the model to 
have AHRF, 28 actually developed AHRF. Similarly 
of the 12 patients not predicted by the model to have 
AHRF, 9 actually did not have AHRF.
Logistic regression for survival
The predictors included in the “full” model were age, 
sex, risk-group, APACHE II 0–24, lung compliance at 
0 hours, chest x-ray score at 0 hours, PaO2/FIO2 ratios 
at 0 and 24 hours, ∆A+FN, ∆TFN, and an intercept 
term. The aim is to predict survival status using clini-
cal variables, separately from AHRF or ARDS status. 
However, as PaO2/FIO2 ratios constitute an essen-
tial part of AHRF or ARDS diagnoses,30,37 they may 
be viewed as proxies for lung injury in a model for 
survival. Of the variables in the full model, only the 
PaO2/FIO2 ratio at 24 hours (PaO2/FIO2(24)), ∆A+FN 
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Table 1. Subject characteristics.1
sepsis  
(n = 24)
Trauma  
(n = 33)
combined group 
(n = 57)
Age 49.0 ± 16.5 38.4 ± 18.2 42.8 ± 18.1
% male 62.5 60.6 61.4
% ArDS 66.7 45.5 54.4
% AhrF 87.5 63.6 73.7
% survival 62.5 66.7 64.9
Lung compliance at 0 h 43.7 ± 12.0 45.0 ± 19.9 44.6 ± 17.4
APAche II 0–24 h 23.8 ± 8.5 21.8 ± 9.3 22.6 ± 8.9
cXr score 0 h 2.0 ± 1.0 1.2 ± 1.1 1.5 ± 1.1
PaO2/FiO2 at 0 h 158.7 ± 92.3 254.5 ± 103.0 218.1 ± 108.8
PaO2/FiO2 at 24 h 181.3 ± 111.2 254.4 ± 97.6 225.5 ± 108.2
∆TFn 0–24 h -14.5 ± 38.5 18.8 ± 62.5 4.7 ± 55.7
∆eIIIA + Fn 0–24 h 2.0 ± 1.9 6.8 ± 3.1 4.7 ± 3.6
risk-to-draw, all patients (h)2 16.8 ± 12.1 17.6 ± 7.0 17.3 ± 9.1
Admit-to-draw, all patients (h)3 97.6 ± 135.0 15.0 ± 8.1 46.4 ± 91.5
risk-to-draw, patients analyzed for progression  
to ArDS or AhrF (n = 45) (h)4
16.8 ± 12.1 17.2 ± 6.9 17.0 ± 9.3
risk-to-draw, patients analyzed for survival  
(n = 34) (h)5
17.8 ± 12.7 18.3 ± 6.3 18.1 ± 9.1
notes: 1Data are expressed as the average ± standard deviation; 2risk-to-draw = the time in hours from initial diagnosis of either major trauma or sepsis 
syndrome to the time of the 0 h (first) blood draw. Data were available for 50 (19 sepsis and 31 trauma) patients; 3Admit-to-draw = the time in hours from 
hospital admission to the 0 h (first) blood draw. Data were available for 50 (19 sepsis and 31 trauma) patients; 4In this subgroup, data were available for 
19 sepsis patients and 26 trauma patients; 5In this subgroup, data were available for 13 sepsis patients and 21 trauma patients.
and risk-group, along with an intercept, remain in the 
best sub-model (Table 2). The odds ratio for a unit 
increase in PaO2/FIO2 ratio (24) is 1.01, with 95% CI 
(1.00, 1.03). Although ∆A+FN and risk-group remain 
in the best sub-model, they are non-significant pre-
dictors using conventional thresholds (see P-values in 
Table 2). Table 3 (bottom) gives a cross-classification 
of observed versus predicted survival status using the 
logistic regression model of Table 2. As can be seen, 
the predictive accuracy of the model for survival is 
relatively good, with 26 out of 34 patients correctly 
classified for outcome.
Associations between AhrF,  
ArDS and survival
Table 4 gives a cross-classification of ARDS or AHRF 
diagnoses and survival among the 57 patients in the 
study sample. It is clear that the patients with ARDS 
or AHRF were significantly less likely to survive, and 
consequently ARDS or AHRF are important predic-
tors of survival in this sample.
Discussion
Using logistic regression analysis, we have observed 
that early changes in TFN constitute covariate 
 predictors for acute lung injury in ICU patients 
with major trauma or sepsis syndrome. Specifically, 
increases in TFN during the first 24 hours of ICU 
observation following diagnosis correlated negatively 
with progression either to the more severe ARDS 
or a milder presentation of acute lung injury, desig-
nated here as AHRF. ∆TFN (negative correlation) 
stood alone as a predictive variable in the best model 
for ARDS and was included with ∆A+FN (positive 
 correlation) and risk-group in the best subset of vari-
ables for prediction of AHRF. The predictive accu-
racy of the AHRF model was relatively good, with 
37 out of 45 patients correctly classified for clinical 
outcome, whereas the model for prediction of ARDS 
exhibited a lower predictive accuracy, with 28 out of 
45 patients correctly classified (Table 3). Of note, the 
time from diagnosis of either major trauma or sepsis 
syndrome to initiation of analysis did not differ, indi-
cating that the study population was homogeneous for 
timing of analysis relative to onset of risk for acute 
lung injury or death.
Although mean initial plasma TFN levels have 
been observed to be higher in medical ICU patients 
who survive than in those who die,16 and lower in 
critically ill patients who progress to acute lung injury 
Fibronectins in the prediction of IcU outcomes
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Table 2. Logistic regression models for ArDS, AhrF, and 
survival.
predictor Coefficient std.  
error
z-value P-value
ARDs
Intercept 0.040 0.326 0.122 0.902
∆TFn -0.016 0.007 -2.408 0.016
AHRF
Intercept -5.645 2.931 -1.926 0.054
risk = sepsis 3.348 1.523 2.199 0.028
∆TFn -0.030 0.011 -2.687 0.007
∆A+Fn 0.503 0.235 2.139 0.032
survival
Intercept -6.680 3.415 -1.956 0.050
risk = sepsis 2.214 1.393 1.590 0.111
PaO2/FIO2(24) 0.014 0.006 2.344 0.019
∆A+Fn 0.263 0.189 1.392 0.164
notes: Estimated coefficients and associated statistics for the best 
submodel chosen by backwards elimination with the AIC. The coefficient 
“risk = sepsis” gives the difference in the log odds of the outcome for the 
sepsis group, as compared to the trauma group, with a positive coefficient 
indicating that the outcome is more likely within the sepsis group, other 
variables being equal. The P-values are for two-sided tests.
Table 3. Observed versus predicted lung injury (ArDS or 
AhrF) and survival status.
predicted status:
ARDs
ArDS no ArDS
Observed status: ArDS 12 10
no ArDS 7 16
AHRF
AhrF no AhrF
Observed status: AhrF 28 3
no AhrF 5 9
survival
Survival Death
Observed status: Survived 17 4
Died 4 9
notes: Observed ArDS and AhrF (using study criteria for diagnosis 
of ARDS and AHRF) and survival status, cross-classified with ARDS, 
AhrF, and survival status as predicted by the logistic regression models 
of Table 2, for the n = 45 cases used to fit the acute lung injury model and 
the n = 34 cases used to fit the survival model. Predicted ARDS, AHRF, or 
survival status is based on assigning patients with estimated probabilities 
of ArDS, AhrF, or survival greater than 0.5 to the “predicted ArDS”, 
“predicted AhrF”, or “predicted survival” groups.
than in those who do not,38 measurements of plasma 
TFN at a single time point have not proven to be 
either sensitive or specific in the prediction of acute 
lung injury.38 In contrast to these earlier studies, we 
have analyzed changes in TFN levels shortly after 
the recognition of major trauma or sepsis  syndrome, 
and found that these correlate negatively with the 
development of either ARDS or AHRF. Since devel-
opment of ARDS or AHRF increases the likelihood 
of death (Table 4), these observations are consistent 
with reports showing that a “rebound” in the circu-
lating level of FN is associated with increased sur-
vival in patients with trauma, sepsis and other critical 
illnesses.1,13,17
Why should rapid early accumulation of FN 
within the circulation correlate with maintenance of 
lung function in patients with vascular tissue injury 
resulting from trauma or sepsis? Since soluble pFN is 
in equilibrium with insoluble FN in the ECM of base-
ment membranes and blood vessel walls,1,18 the rate of 
accumulation of circulating FN after lung microvascu-
lar injury could potentially correlate with rates of FN 
incorporation into pulmonary capillary walls which, 
in turn, could: 1) inhibit apoptosis of cells involved 
in maintenance of the alveolar-capillary barrier, as 
previously observed for neurons in an in vivo model 
of brain tissue injury,4 and 2) reinforce the ECM in 
pulmonary capillary basement membranes, thereby 
increasing barrier function towards solutes.18,20 FN 
also promotes reticuloendothelial clearance of par-
ticulate matter from the circulation, and could there-
fore potentially protect the microcirculation of vital 
organs, including the lungs, from microembolization 
during times of tissue injury.1,19
A+FN expression is triggered at sites of tissue 
injury, where such upregulated expression appears to 
facilitate wound healing.1,39 The association between 
increased A+FN expression and adaptation to tissue 
injury could potentially underlie the observed positive 
associations between ∆A+FN and two disparate clini-
cal outcomes in critically ill patients: AHRF and sur-
vival (Table 2). For example, the association between 
the accumulation of circulating A+FN and AHRF is 
consistent with previous observations that A+FN is 
released into the circulation at sites of experimental 
pulmonary vascular injury/dysfunction in vitro and 
in vivo.40,41 The magnitude of such responses might 
be expected to reflect the extent of pulmonary tissue 
injury, and therefore the relative risk for progression 
to organ dysfunction. Conversely, the positive asso-
ciation between ∆A+FN and survival that we have 
observed, although not significant by conventional 
standards, could reflect the necessity of A+FN for 
healing of injured tissue.39
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Table 4. ArDS or AhrF diagnoses and survival.
Observed survival  
status:
ARDs
Died Survived
Observed ArDS  
status:
ArDS 18 (10.9) 13 (20.1)
no ArDS 2 (9.1) 24 (16.9)
AHRF
Observed AhrF  
status:
AhrF 20 (14.7) 22 (27.3)
no AhrF 0 (5.3) 15 (9.7)
notes: Observed ARDS or AHRF status cross-classified with observed 
survival status, for the n = 57 cases in the total study sample. expected 
counts under the null-hypothesis of no association between ArDS or 
AhrF status and survival are given in parentheses. For ArDS, the 
chi-square test-statistic is X2 = 15.6 on 1 degree of freedom, with 
P-value approximately 8 × 10-5. For AhrF, the chi-square test-statistic 
is X2 = 11.0 on 1 degree of freedom, with P-value approximately 
9 × 10-4.
Among the strengths of this study is that TFN and 
A+FN were measured simultaneously using a common 
standard antigen.10 Among the several limitations is 
the substantial interval that has passed between the 
analysis reported here and the original work upon 
which it is based. Clinical data collection and the 
assays for TFN and A+FN were performed in the late 
1980’s, as described.10 While the widely accepted 
designation for acute lung injury at the time of the 
original study was ARDS, the focus of lung injury 
research has subsequently shifted toward ALI, an 
earlier stage in the continuum of injury that is likely 
to be more amenable to molecular characterization 
and treatment.30 In an attempt to identify and analyze 
a subset of patients whose condition approximates 
ALI, it was necessary for us to rely on a surrogate 
designation (AHRF) that incorporates parenchymal 
opacities on chest radiograph and the same level of 
hypoxemia as the currently accepted classification of 
ALI.30 We have also studied a relatively small num-
ber of patients, and our focus on those who survived 
for at least 24 hours in the ICU may have biased our 
sample toward subjects who were more likely to 
survive.
Additionally, several centers have reported an 
increase in survival of ARDS patients since the time 
of our original study,42 potentially influencing the use-
fulness of our data. The improvement in ARDS out-
come has been commonly attributed to the use of lung 
protective ventilation, although other enhancements 
in ICU care may also play a role. Despite this, the 
causes and timing of ARDS deaths have not changed 
substantially over time, with most deaths occurring 
later in the course of illness.43 Since the focus of our 
study is on the much earlier phase of vascular injury 
preceding ARDS onset, we feel that the findings pre-
sented here may still be broadly applicable and pro-
vide a foundation for future mechanistic and clinical 
lung injury research.
Finally, our observations do not elucidate a 
specific mechanism for the changes in circulating 
levels of TFN and A+FN that follow major trauma 
or sepsis syndrome. A myriad of physiologic pro-
cesses and cell types could potentially contribute 
to such changes in critically ill patients, including 
vascular fluid shifts associated with disease and 
treatments, altered FN synthesis, nutritional status, 
incorporation of FN into blood clots, and altered 
liver function.1
conclusions
The data presented in this pilot study suggest that early 
TFN accumulation within the circulation of patients 
with trauma or sepsis correlates with reduced odds of 
acute lung injury. Conversely, the data also suggest a 
correlation between the rate of early accumulation of 
A+FN isoforms and development of clinical signs of 
mild lung injury. Although these observations are cor-
relative and, as such, do not demonstrate cause and 
effect, they suggest that TFN could play a role in pro-
tection against acute lung injury in patients with sepsis 
or major trauma. This conjecture is not new, as attempts 
were made in the 1980s to protect critically ill patients 
from acute lung injury and death through infusion of 
pFN or pFN-containing cryoprecipitate. Although these 
research experiments were not successful, they may have 
been confounded by difficulties inherent in the isola-
tion and preparation of FN and in clinical use of protein 
mixtures such as cryoprecipitate.1,19,44 With the advent 
of gene-targeted mice that have been rendered null for 
hepatocyte-derived (EDA-/EDB-) pFN,4 A+FN,39,45 or 
B+FN,46 the effects of specific species of circulating FN 
upon the progression of acute and chronic forms of tis-
sue injury and inflammation can now be tested without 
the necessity for infusion of soluble FNs obtained from 
blood or other external sources.
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List of Abbreviations
FN, fibronectin; TFN, total circulating FN; EDA, the 
alternatively spliced extra domain A of FN; A+FN, 
the subset of FN containing the alternatively spliced 
EDA segment; ARDS, acute respiratory distress syn-
drome; AHRF, acute hypoxemic respiratory failure; 
ICU, intensive care unit; CI, confidence interval; OR, 
odds ratio; ECM, extracellular matrix; pFN, plasma 
FN; EDB, the alternatively spliced extra domain B of 
FN; APACHE, Acute Physiology and Chronic Health 
Evaluation; PaO2, partial pressure of oxygen in arte-
rial blood; FIO2, percentage of oxygen in inspired air.
Key Messages
1. In critically ill patients with acute major trauma or 
sepsis syndrome, early accumulation of the adhe-
sion protein fibronectin within the circulation corre-
lates with reduced odds of progression to acute lung 
injury, manifest either as the Acute Respiratory Dis-
tress Syndrome (ARDS), or a milder injury desig-
nated acute hypoxemic respiratory failure (AHRF).
2. In critically ill patients with acute major trauma 
or sepsis syndrome, early accumulation within the 
circulation of the subcategory of fibronectin iso-
forms containing the alternatively spliced EDA 
segment correlates with increased odds of pro-
gression to AHRF.
3. Different plasma fibronectin isoforms convey dif-
ferent clinical information and may be useful in 
the prediction of distinct clinical outcomes in criti-
cally ill patients.
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